Biogen Partners with Cigna and CVS Health to Promote Access to Contentious Alzheimer’s Drug

Biogen has announced that it will partner with Cigna and CVS Health to improve patient access to aducanumab, which received accelerated FDA approval despite claims that it offers limited clinical benefits. This news comes as payers and other healthcare stakeholders consider a shift to value-based healthcare.

Dr. Steve Miller, executive vice president and chief clinical officer at Cigna, notes, “Alzheimer’s disease imposes a tremendous burden on patients, caregivers and society as a whole,” adding, “Given the known infrastructure challenges in the U.S., we are working to ensure that the patients who will benefit most from this new treatment have a clear path to access it.” Read more here.

(Source: Jeff Lagasse, Healthcare Finance, 6/8/21)